Likelihood of recurrence of colitis is higher with CTLA-4 inhibitor therapy or dual (CTLA-4 inhibitor + PD-1/PD-L1 inhibitor) therapy, and therefore CTLA-4 inhibitor therapy is advised against after severe colitis has subsided. This evidence concerns the gene CTLA4 and colitis.